## Vicente Alfaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2466418/publications.pdf

Version: 2024-02-01

		1684188	1125743	
11	360	5	13	
papers	citations	h-index	g-index	
15	15	15	477	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis. Cancer Chemotherapy and Pharmacology, 2021, 87, 113-124.	2.3	4
2	Lurbinectedin in the treatment of relapsed small cell lung cancer. Future Oncology, 2021, 17, 2279-2289.	2.4	13
3	Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. International Journal of Gynecological Cancer, 2021, 31, 1428-1436.	2.5	4
4	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncology, The, 2020, 21, 645-654.	10.7	247
5	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i> Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	1.6	43
6	Encore abstracts in medical/scientific meetings. Medicina ClÃnica (English Edition), 2015, 144, 477-478.	0.2	1
7	Some considerations on the safety evaluation section of clinical study reports for studies with anticancer drugs. Medical Writing, 2012, 21, 23-25.	0.1	O
8	Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis. Cancer Chemotherapy and Pharmacology, 2011, 68, 1223-1231.	2.3	27
9	Abbreviated Clinical Study Reports with Investigational Medicinal Products for Human Use: Current Guidelines and Recommendations. Croatian Medical Journal, 2007, 48, 871-877.	0.7	8
10	Ensayos clÃnicos, buena práctica de publicación y regulaciones legislativas. Medicina ClÃnica, 2004, 123, 100-103.	0.6	2
11	Good Publication Practice guidelines for clinical trials?. Clinical Pharmacology and Therapeutics, 2003, 74, 97-98.	4.7	5